Clinical Trial Update: Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a monoclonal antibody with or without gp100 peptides plus Montanide ISA-51 in stage IV melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Monoclonal antibody
• Montanide ISA-51 (adjuvant Montanide ISA-51)
• gp100 peptides (gp100 peptide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED